Abbott Makes Good On IDev Buy With Supera Peripheral Stent Approval
This article was originally published in The Gray Sheet
Executive Summary
Abbott announced PMA-approval of the Supera stent, which it gained in a $310 million acquisition of IDev Technologies last year. The approval gives Abbott a device specific for the superficial femoral artery, which the company says is one of the largest and fastest growing segments of the peripheral stent market.